Fremanezumab, one of the anti-calcitonin gene-related peptide monoclonal antibodies, is widely used for migraine prophylaxis. However, its efficacy for headache attributed to glioblastoma has not been reported. We herein report a 66-year-old man who had right temporoparietal glioblastoma which recurred despite surgical and chemo-radiological treatment. He had migraine and headache attributed to glioblastoma, but fremanezumab improved both of them. Our case suggested that fremanezumab's possible efficacy for not only migraine but also headache attributed to intracranial neoplasia.
Keywords: alternative medicine; anti-calcitonin gene-related peptide monoclonal antibodies; fremanezumab; glioblastoma; headache; migraine; pain management; palliative care.
Copyright © 2022, Kawamura et al.